China's Laekna Therapeutics has entered into an exclusive licence agreement with Vasque Bio for LAE118, a novel PI3Kα inhibitor designed to selectively target broad‑spectrum mutations of the p110α catalytic subunit. Under the terms, Vasque secures global rights excluding Greater China, while Laekna retains rights in the region for oncology development. Laekna will receive a USD 10 million upfront payment, equity in Vasque (up to a high‑double‑digit percentage of issued shares, or equivalent cash), and up to USD 507 million in development and sales milestones, plus tiered royalties.

Should Vasque Bio enter qualifying strategic transactions related to LAE118, Laekna may receive additional payments of up to 50% of the deal value. The arrangement enables Laekna to accelerate LAE118's global development across rare disease indications while preserving upside potential through equity participation. The company is actively seeking similar strategic partnerships for its other pipeline assets.

According to PharmCube's NextBiopharm® database, there are currently over a hundred PI3Kα under development globally, including 18 in the clinic. Click here to request a free trial for NextBiopharm®.